Biovica International AB/News/Biovica signs US agreement with leading healthcare provider in Arizona

Biovica signs US agreement with leading healthcare provider in Arizona

19 September 2023 - 09:00

Biovica today announces that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona. The agreement will ensure access to DiviTum® TKa for patients across the partners extensive network covering the southwest region of the United States. This agreement marks Biovica’s first commercial hospital (client bill) agreement.

“We are thrilled to be partnering with this leading healthcare provider and their affiliates. This agreement enables both widespread awareness and access to DiviTum® TKa for patients in the southwest region of the United States.” said Warren Cresswell, President of the Americas at Biovica.

Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com

Provided by: MFN

Biovica International AB

Biovica is a biotech company which develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments....

Learn more about company

Related news

27.09.2023

Cellectis S.A

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cel...

27.09.2023

Cellectis S.A

Cellectis présentera des données précliniques sur des cellules « smart » MUC1- CAR T ciblant le cancer du sein triple négatif à l’occasion de la 38ème réunion annuelle de la Society for Immunotherapy of Cancer (SITC)

NEW YORK, 27 sept. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer des thérapies innovantes pour le traitement de maladies graves, a annoncé aujo...

27.09.2023

Redwood Pharma AB

Redwood Pharma AB meddelar sista dag för handel med BTU och första dag för handel med teckningsoptioner av serie TO 5

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I USA, AUSTRALIEN, JAPAN, KANADA, NYA ZEELAND, SYDAFRIKA, HONGKONG, SCHWEIZ, SINGAPORE, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

27.09.2023

Integrum AB

Årsstämmokommuniké – Integrum AB

Resultat- och balansräkningen samt koncernresultat- och koncernbalansräkningen för räkenskapsåret 1 maj 2022–30 april 2023 fastställdes. I enlighet med styrelsens förslag beslutades att inte lämna någon utdelning utan att fritt eget kapital, 151 1...